Here we provide a selection of scientific publications related to IOZK immunotherapy. You can use the filters to make a selection according to tumor types and methods, or enter search terms.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-04-01 / Int. J. Oncol. 2006 Apr;28(4):855-61https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-04-01 / Int. J. Oncol. 2006 Apr;28(4):855-612006-04-01 00:00:002019-02-15 08:32:40Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-03-07 / Ann. Hematol. 2006 May;85(5):308-14https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-03-07 / Ann. Hematol. 2006 May;85(5):308-142006-03-07 00:00:002019-02-15 09:25:36Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-28 / AIDS 2006 Feb;20(4):627-30https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-28 / AIDS 2006 Feb;20(4):627-302006-02-28 00:00:002019-02-15 09:15:17Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-19https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-192006-02-04 00:00:002019-02-15 08:59:59Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-77https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-772006-02-01 00:00:002006-02-01 00:00:00Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-306https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-3062006-02-01 00:00:002019-02-15 08:37:31Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / HBPD INT 2006 Feb;5(1):22-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / HBPD INT 2006 Feb;5(1):22-72006-02-01 00:00:002019-02-15 09:17:43Recent advances in heat shock protein-based cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation
Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma
Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses
Combined action of virus injection and local tumor irradiation on tumor growth in mice
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
Hyperthermia enhances CTL cross-priming
Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA
Therapeutic cancer vaccines
Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate
Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens
Novel immunotherapeutic approaches to glioma
Recent advances in heat shock protein-based cancer vaccines
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes